- Home
- INFA vs GH Comparison
INFA vs GH Comparison
Compare INFA & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INFA
- GH
- Stock Information
- Founded
- INFA 1993
- GH 2011
- Country
- INFA United States
- GH United States
- Employees
- INFA N/A
- GH N/A
- Industry
- INFA EDP Services
- GH Medical Specialities
- Sector
- INFA Technology
- GH Health Care
- Exchange
- INFA Nasdaq
- GH Nasdaq
- Market Cap
- INFA 5.6B
- GH 5.5B
- IPO Year
- INFA 2021
- GH 2018
- Fundamental
- Price
- INFA $24.01
- GH $40.62
- Analyst Decision
- INFA Hold
- GH Strong Buy
- Analyst Count
- INFA 15
- GH 21
- Target Price
- INFA $26.21
- GH $52.81
- AVG Volume (30 Days)
- INFA 6.9M
- GH 2.3M
- Earning Date
- INFA 05-07-2025
- GH 04-30-2025
- Dividend Yield
- INFA N/A
- GH N/A
- EPS Growth
- INFA 215.78
- GH N/A
- EPS
- INFA 0.00
- GH N/A
- Revenue
- INFA $1,655,308,000.00
- GH $773,996,000.00
- Revenue This Year
- INFA $5.12
- GH $23.05
- Revenue Next Year
- INFA $4.81
- GH $21.40
- P/E Ratio
- INFA $3,761.36
- GH N/A
- Revenue Growth
- INFA 2.29
- GH 28.20
- 52 Week Low
- INFA $15.65
- GH $20.14
- 52 Week High
- INFA $31.65
- GH $52.92
- Technical
- Relative Strength Index (RSI)
- INFA 79.78
- GH 48.45
- Support Level
- INFA $18.78
- GH $37.73
- Resistance Level
- INFA $24.33
- GH $39.63
- Average True Range (ATR)
- INFA 0.80
- GH 1.60
- MACD
- INFA 0.52
- GH -0.01
- Stochastic Oscillator
- INFA 89.55
- GH 60.00
About INFA Informatica Inc.
Informatica Inc provides artificial intelligence (AI) enabled data management products on a cloud native platform that connects, manages, and unifies data across multi-vendor, multi-cloud, and hybrid systems at an enterprise scale. The company's platform includes a suite of interoperable data management products that leverage the shared services and metadata of the underlying platform, including products for Data Catalog, Data Integration & Engineering, API & Application Integration, Data Quality and Observability, Master Data Management, Customer and Business 360 Applications, Governance, Access and Privacy, and Data Marketplace., allowing customers to track and understand their data. Geographically, the company generates maximum revenue from North America.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.